Acute phase of SARS-CoV-2 | |||||
SARS-CoV-2 positive (n=3 56 421) | SARS-CoV-2 negative (n=3 067 456) | Standardised mean difference | SARS-CoV-2 negative, PS-weighted (n=356 397) | Standardised mean difference, weighted | |
Demographics | |||||
Sex, female, n% | 182 770 (51) | 1 619 362 (53) | 0.03 | 182 769 (51) | 0.00 |
Age | |||||
18–50 | 246 986 (69) | 1 723 629 (56) | 0.27 | 245 676 (69) | 0.01 |
51–69 | 80 483 (23) | 899 064 (29) | 0.15 | 81 450 (23) | 0.01 |
70+ | 28 952 (8) | 444 763 (14) | 0.20 | 29 271 (8.2) | 0.00 |
Comorbidities | |||||
Charlson Comorbidity Index, n (%) | |||||
CCI=0 | 310 799 (87) | 2 572 424 (84) | 0.09 | 312 217 (88) | 0.01 |
CCI=1 | 10 050 (2.8) | 119 385 (3.9) | 0.06 | 10 430 (2.9) | 0.01 |
CCI≥2 | 35 572 (10.0) | 375 647 (12) | 0.07 | 33 750 (9.5) | 0.02 |
Hypertension | 25 272 (7.1) | 319 755 (10) | 0.12 | 25 310 (7.1) | 0.00 |
Atrial fibrillation or flutter | 8648 (2.4) | 110 716 (3.6) | 0.07 | 8671 (2.4) | 0.00 |
Congestive heart failure | 4.328 (1.2) | 52 125 (1.7) | 0.04 | 4347 (1.2) | 0.00 |
Ischaemic cardiac disease | 13 424 (3.8) | 165 360 (5.4) | 0.08 | 13 431 (3.8) | 0.00 |
Peripheral vascular disease | 2939 (0.8) | 42 398 (1.4) | 0.05 | 2945 (0.8) | 0.00 |
Venous thromboembolism | 6459 (1.8) | 70 198 (2.3) | 0.03 | 6472 (1.8) | 0.00 |
Diabetes mellitus | 11 351 (3.2) | 119 199 (3.9) | 0.04 | 11 402 (3.2) | 0.00 |
Chronic kidney disease | 2882 (0.8) | 30 437 (1.0) | 0.02 | 2896 (0.8) | 0.00 |
Dyslipidaemia | 11 496 (3.2) | 142 515 (4.6) | 0.07 | 11 512 (3.2) | 0.00 |
Cancer | 14 267 (4.0) | 196 123 (6.4) | 0.11 | 14 276 (4.0) | 0.00 |
Lifestyle-related diagnoses | |||||
Alcohol-related disorders | 3068 (0.9) | 50 713 (1.7) | 0.07 | 3076 (0.9) | 0.00 |
Obesity | 24 859 (7.0) | 231 374 (7.5) | 0.02 | 24 928 (7.0) | 0.00 |
Markers of smoking | 10 370 (2.9) | 134 348 (4.4) | 0.08 | 10 393 (2.9) | 0.00 |
Prescription drug use | |||||
Platelet inhibitor | 28 249 (7.9) | 369 535 (12) | 0.14 | 28 284 (7.9) | 0.00 |
Anticoagulants | 14 024 (3.9) | 176 364 (5.7) | 0.08 | 14 057 (3.9) | 0.00 |
Antidiabetic drugs | 20 353 (5.7) | 199 646 (6.5) | 0.03 | 20 405 (5.7) | 0.00 |
Antihypertensives | 75 773 (21) | 890 967 (29) | 0.18 | 75 821 (21) | 0.00 |
Loop diuretics | 15 284 (4.3) | 195 276 (6.4) | 0.09 | 15 336 (4.3) | 0.00 |
Lipid-lowering drugs | 42 273 (12) | 542 350 (18) | 0.16 | 42 272 (12) | 0.00 |
PS, propensity score.